基于远程医疗的乡村诊所老年患者房颤与心力衰竭综合管理
2026年7月25日 更新者:Jiangsu Taizhou People's Hospital
基于远程医疗的农村诊所老年患者心房颤动与心力衰竭综合管理:MIRACLE-AF II整群随机试验
这项整群随机临床试验旨在评估中国农村卫生室中,针对同时患有房颤(AF)和心力衰竭(HF)的老年人(65-80岁)开展的、以村医为主导的远程医疗综合管理项目。
研究旨在探讨:与传统常规护理相比,该数字化支持项目是否能在12个月时通过MAGGIC评分改善心力衰竭预后,并在36个月内降低复合终点事件(如心血管死亡、卒中或心力衰竭住院)的风险。
在本研究中,村卫生室将被随机分配至干预组或对照组。
对照组参与者将接受传统常规护理和基本公共卫生服务,而干预组参与者将接受由村医主导的综合管理项目。
该干预包括由数字健康平台指导、远程专家支持的优化药物治疗,以及结构化的多维生活方式干预,其特色为同伴支持小组锻炼、智能可穿戴设备监测和个性化健康教育。
研究概览
详细说明
心房颤动(AF)与心力衰竭(HF)常同时存在并相互加剧,形成一个“恶性循环”,在老年人中尤为有害。 患有AF的老年患者心力衰竭进展风险高,AF-HF共病是长期预后的核心决定因素。 在中国农村地区,有效的预防和长期管理面临实际瓶颈,包括早期HF筛查不足和针对性预防强度不够。 先前研究表明,仅靠“流程导向”的整合(如标准ABC路径)可能不足以应对HF风险占主导地位的农村AF患者。
为弥补这些不足,MIRACLE-AF II研究旨在建立一种由乡村医生主导的模式,将指南指导的药物治疗(GDMT)与多维生活方式干预相结合,并辅以远程医疗和智能决策支持。 通过将早期HF筛查、药物可及性和可扩展的生活方式干预(包括同伴组心脏康复、行为教育和智能可穿戴设备监测)整合到远程支持的工作流程中,该项目致力于有效改善老年患者的临床结局。
这是一项在中国江苏省农村地区进行的整群随机对照试验。 村诊所以1:1的比例随机分配到数字智能整合管理组(干预)或常规管理组(对照)。 研究纳入65至80岁、确诊为AF并有HF病史或筛查诊断的常住居民。 试验分为两个阶段:12个月随访以比较两组间的HF预后评分(MAGGIC评分),以及36个月随访以比较复合终点事件,包括心血管死亡、缺血性或出血性卒中、因HF恶化或急性冠脉综合征(ACS)住院以及AF急诊就诊。
研究类型
介入性
注册 (估计的)
942
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Ming Chu
- 电话号码:13814010410
- 邮箱:chuming@njmu.edu.cn
学习地点
-
-
Dongtai
-
Yancheng、Dongtai、中国、224200
- 招聘中
- Village Clinics in Dongtai City, Jiangsu Province
-
接触:
- Cheng Wu
- 电话号码:18012515515
- 邮箱:wucheng1413@163.com
-
-
Jiangdu
-
Yangzhou、Jiangdu、中国、225267
- 招聘中
- Village Clinics in Jiangdu District, Jiangsu Province
-
接触:
- Ming Chu
- 电话号码:13814010410
- 邮箱:chuming@njmu.edu.cn
-
-
Suining
-
Xuzhou、Suining、中国、221200
- 招聘中
- Village Clinics in Suining County, Jiangsu Province
-
接触:
- Wensu Chen
- 电话号码:15050848274
- 邮箱:Chen.wensu@163.com
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 年长者
接受健康志愿者
不
描述
纳入标准:
- 江苏省常住户籍居民,年龄65-80岁。
- 经心电图(ECG)确诊为房颤(AF)或持有专科医师出具的房颤诊断证明。
- 有明确心力衰竭(HF)病史,或基于超声心动图和/或NT-proBNP筛查诊断为HF,定义为存在典型HF症状和/或体征,并符合以下任一条件:左心室射血分数降低(HFrEF;LVEF < 40%)、左心室射血分数轻度降低(HFmrEF;LVEF 40-49%),或左心室射血分数保留伴NT-proBNP升高及心脏结构改变(HFpEF;LVEF ≥ 50%,且满足以下至少一项标准:LAV 40 ml/m²、E/e' ≥ 15,或TRV > 2.8 m/s)。
- 由居住地附近的村卫生室进行管理。
- 能够理解研究流程并提供书面知情同意。
排除标准:
- 预期寿命不足3个月。
- 严重肾功能不全(Ccr < 30ml/min)或正在接受透析治疗。
- 由可纠正原因导致的心力衰竭,包括甲状腺功能亢进性心脏病、贫血性心脏病或未矫正的先天性心脏病。
- 有起搏器植入指征但未接受植入。
- 慢性阻塞性肺疾病(COPD)并发II型呼吸衰竭。
- 特殊人群,包括精神疾病患者。
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intervention Group
Participants in this arm will receive village-doctor led integrated care for atrial fibrillation and heart failure.
Village doctors will receive standardized training based on the AF ABC pathway and heart failure GDMT principles.
Patients will receive structured self-management education focused on medication adherence, symptom monitoring, lifestyle modification, and recognition of warning signs.
|
|
|
有源比较器:Control Group
Participants in this arm will receive usual chronic disease management according to the National Basic Public Health Service requirements.
|
Usual care includes routine follow-up, general health education, medication registration, and standard referral procedures provided by local primary care providers.
Participants will not receive the structured village-doctor led integrated care program.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in MAGGIC Heart Failure Risk Score
大体时间:Baseline to 12 months
|
A heart failure prognostic model integrating 13 key predictors, including age, LVEF, systolic blood pressure, BMI, serum creatinine, NYHA functional class, and medication status.
|
Baseline to 12 months
|
|
Composite Cardiovascular Endpoint
大体时间:36 months after baseline
|
Composite cardiovascular endpoint, including cardiovascular death, ischemic or hemorrhagic stroke, hospitalization for worsening heart failure or acute coronary syndrome, and emergency visits due to atrial fibrillation.
|
36 months after baseline
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cardiovascular Death
大体时间:12 months after baseline
|
Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin.
Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular death
|
12 months after baseline
|
|
Cardiovascular Hospitalization
大体时间:12 months after baseline
|
Hospitalization due to cardiovascular or neurological diseases at township-level or higher hospitals, including heart failure, cardiac arrhythmia, acute coronary syndrome, hypertensive emergency or urgency, ischemic or hemorrhagic stroke, and transient ischemic attack.
|
12 months after baseline
|
|
Emergency Visit for Cardiovascular Events
大体时间:12 months after baseline
|
Incidence of emergency visits for cardiovascular events, including exacerbation of heart failure or acute coronary syndrome.
|
12 months after baseline
|
|
ischemic or hemorrhagic Stroke
大体时间:12 months after baseline
|
All strokes: ischemic or hemorrhagic Stroke
|
12 months after baseline
|
|
The proportion of patients who met all the three criteria for the ABC pathway of integrated AF care
大体时间:12 month after baseline
|
The 'A' criterion referred to stroke prevention or anticoagulation.
'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) >65%.
Patients who were not properly treated with OACs are considered as 'A non-compliant'.
The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control.
Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant').
On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled.
The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities.
'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated.
Otherwise, patients were considered as 'C non-compliant'
|
12 month after baseline
|
|
GDMT medication utilization rate
大体时间:12months after baseline
|
The proportion of patients who are eligible for guideline-directed medical therapy (GDMT) and actually receive GDMT within 12 Months.
Single-class prescription rate: Prescription rate for a given GDMT drug class = (number of patients prescribed that drug class) / (number of patients eligible for that drug class) × 100%.
At least one GDMT class prescription rate: At least one GDMT prescription rate = (number of patients prescribed at least one GDMT drug class) / (total number of patients eligible for GDMT) × 100%.
Quadruple GDMT prescription rate: Quadruple therapy prescription rate = (number of patients simultaneously prescribed ARNI/ACEI/ARB + β-blocker + MRA + SGLT2 inhibitor) / (number of patients eligible for all four drug classes) × 100%.
|
12months after baseline
|
|
Cardiovascular Death
大体时间:36 months after baseline
|
Cardiovascular death was defined as death attributable to myocardial infarction, heart failure, arrhythmia, cardiac perforation or tamponade, or other deaths of cardiac origin.
Death caused by ischemic stroke, hemorrhagic stroke, peripheral embolism, and pulmonary embolism was also classified as cardiovascular deathTime
|
36 months after baseline
|
|
Ischemic or hemorrhagic Stroke
大体时间:36 months after baseline
|
All strokes: ischemic or hemorrhagic Stroke
|
36 months after baseline
|
|
Worsening of heart failure or acute coronary syndrome
大体时间:36 months after baseline
|
A worsening of heart failure or acute coronary syndrome was defined as the need to be hospitalized or have an emergency visit in conjunction with these conditions
|
36 months after baseline
|
|
Emergency visit due to AF
大体时间:36 months after baseline
|
Emergency visit due to AF
|
36 months after baseline
|
|
All-cause mortality
大体时间:36 months after baseline
|
all-cause death
|
36 months after baseline
|
|
The proportion of patients who met all the three criteria for the ABC pathway
大体时间:36 month after baseline
|
The 'A' criterion referred to stroke prevention or anticoagulation.
'A criterion compliant' implies that either appropriate non-vitamin K antagonist oral anticoagulant (NOACs) use, or warfarin was used with a time in the therapeutic range (TTR) >65%.
Patients who were not properly treated with OACs are considered as 'A non-compliant'.
The 'B' criterion referred to better symptom control with patient-centered decisions on rate or rhythm control.
Patients with an EHRA score of I or II are considered to have good control of AF symptoms ('B compliant').
On the contrary, those with an EHRA score of III or IV were defined as 'B non-compliant', which means their symptoms were insufficiently controlled.
The 'C' criterion stands for optimal management of cardiovascular risk factors and other comorbidities.
'C criterion compliant' implies that all the considered risk factors and comorbidities were well controlled or optimally treated.
Otherwise, patients were considered as 'C non-compliant'
|
36 month after baseline
|
|
Change in MAGGIC Heart Failure Risk Score
大体时间:Baseline to 36 months
|
Description: A heart failure prognostic model integrating 13 key predictors, including age, LVEF, systolic blood pressure, BMI, serum creatinine, NYHA functional class, and medication status.
|
Baseline to 36 months
|
|
GDMT Score
大体时间:Baseline to 12 months
|
β-blockers are scored as 0, 1, or 2 points for no use, use at <50% of the target dose, or use at ≥50% of the target dose, respectively.
For renin-angiotensin system inhibitors, no use is scored as 0 points; ACEI/ARB therapy at <50% or ≥50% of the target dose is scored as 1 or 2 points, respectively; and ARNI therapy at any dose is scored as 3 points.
Mineralocorticoid receptor antagonists and SGLT2 inhibitors are each scored as 0 points when not used and 2 points when used at any dose.
Ivabradine and vericiguat are each scored as 0 points when not used and 1 point when used at any dose.
The scores for all medication classes are summed to obtain the total GDMT score, with a higher score indicating a greater degree of GDMT implementation.
Target doses are determined according to the relevant heart failure guidelines.
|
Baseline to 12 months
|
|
GDMT Score
大体时间:Baseline to 36 months
|
β-blockers are scored as 0, 1, or 2 points for no use, use at <50% of the target dose, or use at ≥50% of the target dose, respectively.
For renin-angiotensin system inhibitors, no use is scored as 0 points; ACEI/ARB therapy at <50% or ≥50% of the target dose is scored as 1 or 2 points, respectively; and ARNI therapy at any dose is scored as 3 points.
Mineralocorticoid receptor antagonists and SGLT2 inhibitors are each scored as 0 points when not used and 2 points when used at any dose.
Ivabradine and vericiguat are each scored as 0 points when not used and 1 point when used at any dose.
The scores for all medication classes are summed to obtain the total GDMT score, with a higher score indicating a greater degree of GDMT implementation.
Target doses are determined according to the relevant heart failure guidelines.
|
Baseline to 36 months
|
|
GDMT medication utilization rate
大体时间:36 months after baseline
|
The proportion of patients who are eligible for guideline-directed medical therapy (GDMT) and actually receive GDMT within 36 months.
Single-class prescription rate: Prescription rate for a given GDMT drug class = (number of patients prescribed that drug class) / (number of patients eligible for that drug class) × 100%.
At least one GDMT class prescription rate: At least one GDMT prescription rate = (number of patients prescribed at least one GDMT drug class) / (total number of patients eligible for GDMT) × 100%.
Quadruple GDMT prescription rate: Quadruple therapy prescription rate = (number of patients simultaneously prescribed ARNI/ACEI/ARB + β-blocker + MRA + SGLT2 inhibitor) / (number of patients eligible for all four drug classes) × 100%.
|
36 months after baseline
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Chu M, Zhang S, Gong J, Yang S, Yang G, Sun X, Wu D, Xia Y, Jiao J, Peng X, Peng Z, Hong L, Wang Z, Li M, Lip GYH, Chen M; MIRACLE-AF Investigators. Telemedicine-based integrated management of atrial fibrillation in village clinics: a cluster randomized trial. Nat Med. 2025 Apr;31(4):1276-1285. doi: 10.1038/s41591-025-03511-2. Epub 2025 Feb 21.
- Li M, Chu M, Shen Y, Zhang S, Yin X, Yang S, Lip GYH, Chen M; MIRACLE-AF Trial Investigators. A Novel Model of Integrated Care of Older Patients With Atrial Fibrillation in Rural China. JACC Asia. 2024 Jul 30;4(10):764-773. doi: 10.1016/j.jacasi.2024.07.006. eCollection 2024 Oct.
- Li M, Chen Y, Chu M, Zhang S, Yang S, Lip GYH, Chen M. Village Doctor-Led Telemedicine for Rural Patients Aged 75 Years and Older With AF: A Prespecified Secondary Analysis of the MIRACLE-AF Trial. JAMA Netw Open. 2026 Mar 2;9(3):e261385. doi: 10.1001/jamanetworkopen.2026.1385.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年8月1日
初级完成 (估计的)
2029年12月30日
研究完成 (估计的)
2029年12月30日
研究注册日期
首次提交
2026年3月16日
首先提交符合 QC 标准的
2026年3月19日
首次发布 (实际的)
2026年3月25日
研究记录更新
最后更新发布 (实际的)
2026年7月28日
上次提交的符合 QC 标准的更新
2026年7月25日
最后验证
2026年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.